Chinese expert opinion for diagnosis and treatment of colorectal cancer peritoneal metastasis. (2017 edition)

doi:10.3877/cma.j.issn.2095-3224.2017.05.002

Abstract

Abstract:

Colorectal cancer incidence and mortality rates are high in China. Peritoneal as a common site of metastasis, accompanied by high incidence. In addition, the early diagnosis of the disease is difficult, and the prognosis is poor. However, the diagnosis and treatment level of colorectal cancer peritoneal metastasis is uneven, but also has not yet formed a standardized treatment model. Therefore, in order to regulate the diagnosis and treatment of peritoneal metastasis of colorectal cancer, detect the peritoneal metastasis in time, and develop a reasonable and effective multidisciplinary comprehensive treatment program, the relevant experts from Professional Committee of peritoneal metastasis, Colorectal Cancer Committee of Chinese Medical Doctor Association developed ″Chinese expert opinion for diagnosis and treatment of colorectal cancer peritoneal metastasis″. It aimed at improving the overall diagnosis and treatment of colorectal peritoneal metastasis in China to extend the survival time of patients with colorectal cancer and improve the quality of life.

Key words: Colorectal neoplasms, Peritoneal metastasis, Cytoreductive surgery, CRS, Hyperthermic intraperitoneal chemotherapy, HIPEC, Expert opinion

Professional Committee of peritoneal metastasis, Colorectal Cancer Committee of Chinese Medical Doctor Association. Chinese expert opinion for diagnosis and treatment of colorectal cancer peritoneal metastasis. (2017 edition)[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(05): 360-366.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.05.002

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I05/360

Figures/Tables 1

References 41

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[2]	Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3):263-267.
[3]	Yonemura Y, Bandou E, Kawamura T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer[J]. Eur J Surg Oncol, 2006, 32(6):602-606.
[4]	徐惠绵. 胃肠癌腹膜转移的研究进展[J]. 中华结直肠疾病电子杂志, 2015, (01):2-4.
[5]	Fidler IJ. The pathogenesis of cancer metastasis: the ′seed and soil′ hypothesis revisited[J]. Nat Rev Cancer, 2003, 3(6):453-458.
[6]	Ahmed N, Riley C, Rice G, et al. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment[J]. Clin Exp Metastasis, 2005, 22(5):391-402.
[7]	Suzuki HI, Kiyono K, Miyazono K. Regulation of autophagy by transforming growth factor-beta (TGF-beta) signaling[J]. Autophagy, 2010, 6(5):645-647.
[8]	Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis[J]. World J Gastroenterol, 2008, 14(8):1159-1166.
[9]	McMullen JRW, Selleck M, Wall NR, et al. Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy[J]. Oncotarget, 2017, 8(26):43481-43490.
[10]	Baratti D, Kusamura S, Deraco M. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus[J]. J Surg Oncol, 2008, 98(4):258-262.
[11]	Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study[J]. J Surg Oncol, 2010, 102(6):565-570.
[12]	Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT[J]. Abdom Imaging, 2008, 33(1):87-93.
[13]	李雁，周云峰，梁寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识[J]. 中国肿瘤临床, 2015(04):198-206.
[14]	Koh JL, Yan TD, Glenn D, et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis[J]. Ann Surg Oncol, 2009, 16(2):327-333.
[15]	Soussan M, Des Guetz G, Barrau V, et al. Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy[J]. Eur Radiol, 2012, 22(7):1479-1487.
[16]	Yang XQ, Yan L, Chen C, et al. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement[J]. Hepatogastroenterology, 2009, 56(94-95):1388-1394.
[17]	Yang XQ, Chen C, Peng CW, et al. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases[J]. Med Oncol, 2012, 29(2):1030-1036.
[18]	Chen C, Chen LQ, Yang GL, et al. The application of C12 biochip in the diagnosis and monitoring of colorectal cancer: systematic evaluation and suggestion for improvement[J]. J Postgrad Med, 2008, 54(3):186-190.
[19]	Wagner PL, Austin F, Sathaiah M, et al. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin[J]. Ann Surg Oncol, 2013, 20(2):506-514.
[20]	Fujita Y, Terashima M, Hoshino Y, et al. Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer[J]. Gastric Cancer, 2006, 9(4):308-314.
[21]	Ozawa Y, Murakami M, Watanabe M, et al. Preoperative colonic cancer tattooing using the near-infrared fluorescence laparoscopic imaging system[J]. Asian J Endosc Surg, 2016, 9(4):340-343.
[22]	Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment[J]. Expert Opin Pharmacother, 2014, 15(5):623-636.
[23]	Akagi Y, Kinugasa T, Adachi Y, et al. Prognostic significance of isolated tumor cells in patients with colorectal cancer in recent 10-year studies[J]. Mol Clin Oncol, 2013, 1(4):582-592.
[24]	Park EJ, Baik SH, Hur H, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colorectal cancer with peritoneal carcinomatosis: Clinical outcomes at 2 tertiary referral centers in Korea[J]. Medicine (Baltimore), 2017, 96(21):e6632.
[25]	Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1, 013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis[J]. Ann Surg Oncol, 2014, 21(13):4195-4201.
[26]	孙立峰，童舟，丁克峰. 外科肿瘤细胞减灭术联合腹腔内热灌注化疗——结直肠癌腹膜转移治疗的突破方向?[J]. 中华结直肠疾病电子杂志, 2015, (03):234-239.
[27]	Gomez Portilla A, Cendoya I, Lopez de Tejada I, et al. Peritoneal carcinomatosis of colorectal origin. Current treatment. Review and update[J]. Rev Esp Enferm Dig, 2005, 97(10):716-737.
[28]	Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer[J]. Cancer Chemother Pharmacol, 1999, 43 Suppl:S15-25.
[29]	Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy[J]. Cancer Res, 1980, 40(2):256-260.
[30]	Turaga K, Levine E, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States[J]. Ann Surg Oncol, 2014, 21(5):1501-1505.
[31]	Mo S, Cai G. Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature[J]. Gastroenterol Res Pract, 2016, 2016:1516259.
[32]	Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)[J]. GERCOR. Eur J Cancer, 1999, 35(9):1338-1342.
[33]	Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2010, 28(31):4706-4713.
[34]	Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma[J]. J Clin Oncol, 1987, 5(10):1559-1565.
[35]	Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(6):563-572.
[36]	National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) : Colon Cancer Version 1.2017.US. 2015.
[37]	季加孚，沈琳，徐惠绵, 等. 胃癌腹膜转移防治中国专家共识[J]. 中国医学前沿杂志(电子版), 2017(05):29-40.
[38]	Kim JH, Ku YS, Jeon TJ, et al. The efficacy of self-expanding metal stents for malignant colorectal obstruction by noncolonic malignancy with peritoneal carcinomatosis[J]. Dis Colon Rectum, 2013, 56(11):1228-1232.
[39]	Kerscher AG, Chua TC, Gasser M, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades[J]. Br J Cancer, 2013, 108(7):1432-1439.
[40]	Sadahiro S, Suzuki T, Maeda Y, et al. Prognostic factors in patients with synchronous peritoneal carcinomatosis (PC) caused by a primary cancer of the colon[J]. J Gastrointest Surg, 2009, 13(9):1593-1598.
[41]	Mulsow J, Merkel S, Agaimy A, et al. Outcomes following surgery for colorectal cancer with synchronous peritoneal metastases[J]. Br J Surg, 2011, 98(12):1785-1791.

Please choose a citation manager

Content to export